Genomic classification of cutaneous melanoma R Akbani, KC Akdemir, BA Aksoy, M Albert, A Ally, SB Amin, H Arachchi, ... Cell 161 (7), 1681-1696, 2015 | 1429 | 2015 |
Adult mesenchymal stem cells and cell-based tissue engineering RS Tuan, G Boland, R Tuli Arthritis Res Ther 5 (1), 1-14, 2002 | 1074 | 2002 |
Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells GM Boland, G Perkins, DJ Hall, RS Tuan Journal of cellular biochemistry 93 (6), 1210-1230, 2004 | 623 | 2004 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 402 | 2020 |
Defining T cell states associated with response to checkpoint immunotherapy in melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ... Cell 175 (4), 998-1013. e20, 2018 | 368 | 2018 |
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ... Cell 175 (4), 984-997. e24, 2018 | 305 | 2018 |
Resistance to checkpoint blockade therapy through inactivation of antigen presentation M Sade-Feldman, YJ Jiao, JH Chen, MS Rooney, M Barzily-Rokni, ... Nature communications 8 (1), 1-11, 2017 | 271 | 2017 |
Formation and prevention of postoperative abdominal adhesions GM Boland, RJ Weigel Journal of Surgical Research 132 (1), 3-12, 2006 | 247 | 2006 |
Cross‐talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation D Baksh, GM Boland, RS Tuan Journal of cellular biochemistry 101 (5), 1109-1124, 2007 | 209 | 2007 |
CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation J Deng, ES Wang, RW Jenkins, S Li, R Dries, K Yates, S Chhabra, ... Cancer discovery 8 (2), 216-233, 2018 | 190 | 2018 |
Wnt-3A enhances bone morphogenetic protein-2-mediated chondrogenesis of murine C3H10T1/2 mesenchymal cells L Fischer, G Boland, RS Tuan Journal of Biological Chemistry 277 (34), 30870-30878, 2002 | 188 | 2002 |
Toward minimal residual disease-directed therapy in melanoma F Rambow, A Rogiers, O Marin-Bejar, S Aibar, J Femel, M Dewaele, ... Cell 174 (4), 843-855. e19, 2018 | 183 | 2018 |
Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids RW Jenkins, AR Aref, PH Lizotte, E Ivanova, S Stinson, CW Zhou, ... Cancer discovery 8 (2), 196-215, 2018 | 151 | 2018 |
Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer GM Boland, GJ Chang, AB Haynes, YJ Chiang, R Chagpar, Y Xing, ... Cancer 119 (8), 1593-1601, 2013 | 149 | 2013 |
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma N Auslander, G Zhang, JS Lee, DT Frederick, B Miao, T Moll, T Tian, ... Nature medicine 24 (10), 1545-1549, 2018 | 144 | 2018 |
Wnt signaling during BMP‐2 stimulation of mesenchymal chondrogenesis L Fischer, G Boland, RS Tuan Journal of cellular biochemistry 84 (4), 816-831, 2002 | 133 | 2002 |
Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma AE Siroy, GM Boland, DR Milton, J Roszik, S Frankian, J Malke, L Haydu, ... Journal of Investigative Dermatology 135 (2), 508-515, 2015 | 115 | 2015 |
Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy MT Chow, AJ Ozga, RL Servis, DT Frederick, JA Lo, DE Fisher, ... Immunity 50 (6), 1498-1512. e5, 2019 | 113 | 2019 |
Lineage tracing in humans enabled by mitochondrial mutations and single-cell genomics LS Ludwig, CA Lareau, JC Ulirsch, E Christian, C Muus, LH Li, K Pelka, ... Cell 176 (6), 1325-1339. e22, 2019 | 113 | 2019 |
Granzyme B PET imaging as a predictive biomarker of immunotherapy response BM Larimer, E Wehrenberg-Klee, F Dubois, A Mehta, T Kalomeris, ... Cancer research 77 (9), 2318-2327, 2017 | 109 | 2017 |